Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Sell
34
NCNA Quote, Financials, Valuation and Earnings
Last price:
$1.11
Seasonality move
:
2.17%
Day range:
$1.14 - $1.25
52-week range:
$1.06 - $19.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.78x
Volume:
117K
Avg. volume:
180K
1-year change:
-84.67%
Market cap:
$4.5M
Revenue:
--
EPS (TTM):
-$14.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -$0.09 | -- | -98.11% | $64.50 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$8.8M | -$0.15 | 4199.24% | -9.44% | $2.27 |
|
AKTX
Akari Therapeutics PLC
|
-- | -- | -- | -- | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
DBVT
DBV Technologies SA
|
$1.1M | -$0.22 | -- | -59.89% | $22.11 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
$1.15 | $64.50 | $4.5M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.62 | $2.27 | $158.6M | -- | $0.00 | 0% | 0.87x |
|
AKTX
Akari Therapeutics PLC
|
$1.28 | -- | $31.7M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$4.27 | $17.97 | $2.5M | -- | $0.00 | 0% | 3.85x |
|
DBVT
DBV Technologies SA
|
$3.83 | $22.11 | $78.6M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.41 | -- | $3.3M | -- | $0.25 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | 1.546 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 4.431 | 20.51% | 3.54x |
|
AKTX
Akari Therapeutics PLC
|
-- | -0.056 | -- | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.100 | -- | 1.20x |
|
DBVT
DBV Technologies SA
|
-- | -0.335 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.581 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AKTX
Akari Therapeutics PLC
|
-- | -$1.9M | -- | -- | -- | -$1.5M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -$30.3M | -- | -- | -- | -$22.9M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
NuCana PLC vs. Competitors
-
Which has Higher Returns NCNA or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -43.07%. NuCana PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About NCNA or ADAP?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5508.7%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $2.27 which suggests that it could grow by 265.65%. Given that NuCana PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe NuCana PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is NCNA or ADAP More Risky?
NuCana PLC has a beta of 0.973, which suggesting that the stock is 2.67% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.236, suggesting its more volatile than the S&P 500 by 123.631%.
-
Which is a Better Dividend Stock NCNA or ADAP?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or ADAP?
NuCana PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. NuCana PLC's net income of -$5.9M is higher than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, NuCana PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 0.87x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M ADAPAdaptimmune Therapeutics PLC0.87x -- $40.9M -$17.6M
-
Which has Higher Returns NCNA or AKTX?
Akari Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- AKTXAkari Therapeutics PLC-- -$0.24 -- -
What do Analysts Say About NCNA or AKTX?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5508.7%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 6150%. Given that Akari Therapeutics PLC has higher upside potential than NuCana PLC, analysts believe Akari Therapeutics PLC is more attractive than NuCana PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 AKTXAkari Therapeutics PLC0 0 0 -
Is NCNA or AKTX More Risky?
NuCana PLC has a beta of 0.973, which suggesting that the stock is 2.67% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.789, suggesting its less volatile than the S&P 500 by 21.114%.
-
Which is a Better Dividend Stock NCNA or AKTX?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or AKTX?
NuCana PLC quarterly revenues are --, which are smaller than Akari Therapeutics PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, NuCana PLC's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M AKTXAkari Therapeutics PLC-- -- -- -$2.9M
-
Which has Higher Returns NCNA or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About NCNA or BDRX?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5508.7%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 320.87%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is NCNA or BDRX More Risky?
NuCana PLC has a beta of 0.973, which suggesting that the stock is 2.67% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.
-
Which is a Better Dividend Stock NCNA or BDRX?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BDRX?
NuCana PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, NuCana PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 3.85x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M BDRXBiodexa Pharmaceuticals PLC3.85x -- -- --
-
Which has Higher Returns NCNA or DBVT?
DBV Technologies SA has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- DBVTDBV Technologies SA-- -$1.60 -- -
What do Analysts Say About NCNA or DBVT?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5508.7%. On the other hand DBV Technologies SA has an analysts' consensus of $22.11 which suggests that it could grow by 474.73%. Given that NuCana PLC has higher upside potential than DBV Technologies SA, analysts believe NuCana PLC is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 DBVTDBV Technologies SA0 0 0 -
Is NCNA or DBVT More Risky?
NuCana PLC has a beta of 0.973, which suggesting that the stock is 2.67% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.640, suggesting its less volatile than the S&P 500 by 36.023%.
-
Which is a Better Dividend Stock NCNA or DBVT?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or DBVT?
NuCana PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. NuCana PLC's net income of -$5.9M is higher than DBV Technologies SA's net income of -$30.4M. Notably, NuCana PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M DBVTDBV Technologies SA-- -- -- -$30.4M
-
Which has Higher Returns NCNA or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana PLC-- -$2.28 -- TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About NCNA or TCBP?
NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5508.7%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 492.59%. Given that NuCana PLC has higher upside potential than TC BioPharm (Holdings) PLC, analysts believe NuCana PLC is more attractive than TC BioPharm (Holdings) PLC.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana PLC1 2 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is NCNA or TCBP More Risky?
NuCana PLC has a beta of 0.973, which suggesting that the stock is 2.67% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NCNA or TCBP?
NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. NuCana PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or TCBP?
NuCana PLC quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, NuCana PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana PLC-- -- -- -$5.9M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 10
IonQ [IONQ] is up 7.07% over the past day.
Sell
47
CEG alert for Jan 10
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
8
CRNX alert for Jan 10
Crinetics Pharmaceuticals [CRNX] is down 16.31% over the past day.
